Analysts’ Top Healthcare Picks: Alimera (ALIM), uniQure NV (QURE)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alimera (ALIM) and uniQure NV (QURE) with bullish sentiments.

Alimera (ALIM)

B.Riley FBR analyst Andrew D’silva assigned a Buy rating to Alimera today and set a price target of $3.05. The company’s shares opened today at $0.95.

D’silva wrote:

“Alimera Sciences, Inc. (ALIM) reported 1Q19 results Monday, 4/28, and will hold a conference call at 9:00am ET Tuesday, 4/30. The dial-in number for ALIM’s earnings call is . The company posted a top-line/adj. EPS/adj. EBITDA of $12.9M/$(0.04)/$0.0M versus our/ consensus estimates of $12.5M/$(0.06)/$(0.9)M and $12.3M/$(0.04)/$(0.4)M , respectively. The top-line variance relative to our estimate was primarily tied to international Iluvien sales coming in above our estimates, which appears to have benefited from the Ozurdex supply constraints that Allergan has been facing, and initial sales into France and other countries. The print strengthens our belief that ALIM will show Y/Y improvement to its top-line, as it continues to expand its first-time patient base with Iluvien for diabetic macular edema (DME).”

According to TipRanks.com, D’silva is a 4-star analyst with an average return of 7.0% and a 39.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Sensus Healthcare Inc, and Anixa Biosciences Inc.

Alimera has an analyst consensus of Moderate Buy, with a price target consensus of $2.90.

See today’s analyst top recommended stocks >>

uniQure NV (QURE)

B.Riley FBR analyst George Zavoico reiterated a Buy rating on uniQure NV yesterday and set a price target of $72. The company’s shares opened today at $56.33.

According to TipRanks.com, Zavoico is a 4-star analyst with an average return of 7.0% and a 45.2% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Corbus Pharmaceuticals, Geron Corp, and Novavax.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $79.50, representing a 41.1% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts